GlassScriptPhysician profile
Donald C Ingle
NPI 1972563492
$3,922.88
in general payments reported to CMS, 2019-2025
39 companies · $877 in 2025
The $877 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $195 · 2021: $107 · 2022: $307 · 2023: $936 · 2024: $1,034 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,846.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $790.27 | 2021-2025 | |
| Lilly USA, LLC | $464.15 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.84 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $324.79 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $259.04 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $200.51 | 2023-2025 | |
| Novo Nordisk INC | $149.20 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $135.56 | 2019-2025 | Veozah |
| Tris Pharma INC | $121.84 | 2024 | Quillivant, Dyanavel Xr, Quillichew Er |
| Janssen Pharmaceuticals, INC | $114.02 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $98.72 | 2019-2025 | Airsupra, Breztri |
| Dexcom, INC. | $80.45 | 2023-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $76.45 | 2022-2024 | Rexulti |
| Allergan, INC. | $66.21 | 2019-2020 | |
| Amgen INC. | $63.95 | 2019-2024 | Repatha, Otezla |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Ingle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.